METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A PD-L1 BINDING ANTAGONIST FOR TREATING LUNG CANCER

Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).

Saved in:
Bibliographic Details
Main Authors JOO, Stephanie Royer, SCHUTZMAN, Jennifer Lee, MERCHANT, Mark Andrew, MANDLEKAR, Sandhya Vinayak, EVANGELISTA, Marie, LIN, Ting-Kun Mark
Format Patent
LanguageEnglish
Published 11.05.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).
Bibliography:Application Number: AU20210378793